News & Updates
Filter by Specialty:
Intensive urate lowering of little benefit to patients with erosive gout
A more intensive serum urate-lowering therapy falls short of improving bone erosion scores in patients with erosive gout, in addition to being associated with a high treatment burden, as shown in a study.
Intensive urate lowering of little benefit to patients with erosive gout
27 Apr 2022
US-guided corticosteroid injection relieves symptoms in hip OA
An ultrasound (US)-guided intra-articular hip injection of corticosteroid and local anaesthetic, administered with advice and education, results in a rapid and sustained symptom response for individuals with hip osteoarthritis (OA), a study has shown.
US-guided corticosteroid injection relieves symptoms in hip OA
20 Apr 2022
BMI mediates pain severity in hands, lower extremities in patients with hand OA
In patients with hand osteoarthritis (OA), the higher the body mass index (BMI), the more severe the pain in the hands, feet, and knees/hips is, according to a study. The generalized pain experienced by overweight or obese OA patients may be attributed to low-grade inflammation.
BMI mediates pain severity in hands, lower extremities in patients with hand OA
02 Apr 2022
Rheumatoid arthritis in moms aggravates mental disorders in kids
Children born to mothers with rheumatoid arthritis (RA) are at higher risk of major mental disorders such as autism spectrum disorders (ASD) and attention-deficit/hyperactivity disorder (ADHD), a recent Taiwan study has found. No such effect exists for paternal RA.
Rheumatoid arthritis in moms aggravates mental disorders in kids
30 Mar 2022
Language, math scores poorer in adolescents with childhood-onset chronic rheumatic disease
Patients with childhood-onset chronic rheumatic disease (CRD) do not perform as well as their peers on grade 12 standardized testing, independent of sociodemographic and mental health comorbidities, reports a population-based retrospective cohort study.
Language, math scores poorer in adolescents with childhood-onset chronic rheumatic disease
27 Mar 2022
TYK2 inhibitor for psoriatic arthritis clears phase II trial
In the treatment of patients with psoriatic arthritis, the use of the selective TYK2 inhibitor deucravacitinib appears to be effective and well tolerated, leading to greater improvements in American College of Rheumatology (ACR) domains, enthesitis endpoints, and multiple patient-reported, psoriasis-related outcomes relative to placebo, as shown in the results of a phase II trial.